Medications used to reduce the risk of osteoporosis-related fractures are classified as antiresorptive agents (that suppress osteoclast-mediated bone resorption) or anabolic therapies (that promote new bone formation by activating osteoblasts). Antiresorptive medications have already been reviewed.1 This JAMA Insights discusses the use of anabolic medications, including teriparatide, abaloparatide, and romosozumab.
Ensrud KE, Schousboe JT. Anabolic Therapy for Osteoporosis. JAMA. 2021;326(4):350–351. doi:10.1001/jama.2021.0233
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: